研究業績-2017｜糖尿病 食事療法 治療 京大病院 栄養内科
Suzuki K, Iwasaki K, Murata Y, Harada N, Yamane S, Hamasaki A, Shibue K, Joo E, Sankoda A, Fujiwara Y, Hayashi Y, Inagaki N. Distribution and hormonal characterization of primary murine L-cells throughout the gastrointestinal tract. J Diabetes Investig. 2017 Apr 20. doi: 10.1111/jdi.12681. [Epub ahead of print]
Wang Y, Harashima SI, Liu Y, Usui R, Inagaki N. Sphingosine kinase 1-interacting protein is a novel regulator of glucose-stimulated insulin secretion. Sci Rep. 2017 Apr 10;7(1):779. doi: 10.1038/s41598-017-00900-7.
Nakamura J, Kamiya H, Haneda M, Inagaki N, Tanizawa Y, Araki E, Ueki K, Nakayama T. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: Report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig. 2017 Mar 27. doi: 10.1111/jdi.12645. [Epub ahead of print]
Sankoda A, Harada N, Iwasaki K, Yamane S, Murata Y, Shibue K, Thewjitcharoen Y, Suzuki K, Harada T, Kanemaru Y, Shimazu-Kuwahara S, Hirasawa A, Inagaki N. Long chain free fatty acid receptor GPR120 mediates oil-induced GIP secretion through CCK in male mice. Endocrinology. 2017 Mar 15. doi: 10.1210/en.2017-00090. [Epub ahead of print]
Komatsu T, Chen-Yoshikawa TF, Oshima A, Harashima SI, Aoyama A, Inagaki N, Date H. Severe underweight decreases the survival rate in adult lung transplantation. Surg Today. 2017 Mar 17. doi: 10.1007/s00595-017-1508-8. [Epub ahead of print]
Shimazu-Kuwahara S, Harada N, Yamane S, Joo E, Sankoda A, Kieffer TJ, Inagaki N. Attenuated secretion of glucose-dependent insulinotropic polypeptide (GIP) does not alleviate hyperphagic obesity and insulin resistance in ob/ob mice. Mol Metab. 2017 Jan 19;6(3):288-294. doi: 10.1016/j.molmet.2017.01.006. eCollection 2017 Mar.
Shibue K, Fujii T, Goto H, Yamashita Y, Sugimura Y, Tanji M, Yasoda A, Inagaki N. Rapid exacerbation of lymphocytic infundibuloneurohypophysitis. Medicine (Baltimore). 2017 Mar;96(9):e6034. doi: 10.1097/MD.0000000000006034.
Nishimura A, Harashima SI, Fukushige H, Wang Y, Liu Y, Hosoda K, Inagaki N. A Large Difference in Dose Timing of Basal Insulin Introduces Risk of Hypoglycemia and Overweight: A Cross-Sectional Study. Diabetes Ther. 2017 Apr;8(2):385-399. doi: 10.1007/s13300-017-0238-7. Epub 2017 Feb 24.
Ueki J, Nakamori M, Nakamura M, Nishikawa M, Yoshida Y, Tanaka A, Morizane A, Kamon M, Araki T, Takahashi MP, Watanabe A, Inagaki N, Sakurai H. Myotonic dystrophy type 1 patient-derived iPSCs for the investigation of CTG repeat instability. Sci Rep. 2017 Feb 13;7:42522. doi: 10.1038/srep42522.
Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Iijima H, Watanabe Y, Gouda M. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017 Feb 8. doi: 10.1111/dom.12898. [Epub ahead of print]
Fujita Y, Inagaki N. Metformin: New Preparations and Nonglycemic Benefits. Curr Diab Rep. 2017 Jan;17(1):5. doi: 10.1007/s11892-017-0829-8. Review.
Joo E, Harada N, Yamane S, Fukushima T, Taura D, Iwasaki K, Sankoda A, Shibue K, Harada T, Suzuki K, Hamasaki A, Inagaki N. Inhibition of Gastric Inhibitory Polypeptide Receptor Signaling in Adipose Tissue Reduces Insulin Resistance and Hepatic Steatosis in High-Fat Diet-Fed Mice. Diabetes. 2017 Apr;66(4):868-879. doi: 10.2337/db16-0758. Epub 2017 Jan 17..
Kimura H, Matsuda H, Ogawa Y, Fujimoto H, Toyoda K, Fujita N, Arimitsu K, Hamamatsu K, Yagi Y, Ono M, Inagaki N, Saji H. Development of 111In-labeled exendin(9-39) derivatives for single-photon emission computed tomography imaging of insulinoma. Bioorg Med Chem. 2017 Feb 15;25(4):1406-1412. doi: 10.1016/j.bmc.2016.12.051. Epub 2017 Jan 3.
Tanaka H, Takano K, Iijima H, Kubo H, Maruyama N, Hashimoto T, Arakawa K, Togo M, Inagaki N, Kaku K. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus. Adv Ther. 2017 Feb;34(2):436-451. doi: 10.1007/s12325-016-0457-8. Epub 2016 Dec 15.
Harashima SI, Nishimura A, Inagaki N. Attitudes of patients and physicians to insulin therapy in Japan: an analysis of the Global Attitude of Patients and Physicians in Insulin Therapy study. Expert Opin Pharmacother. 2017 Jan;18(1):5-11. doi: 10.1080/14656566.2016.1260547. Epub 2016 Dec 5.
Nishimura A, Harashima SI, Fujita Y, Tanaka D, Wang Y, Liu Y, Inagaki N. Effects of structured testing versus routine testing of blood glucose in diabetes self-management: A randomized controlled trial. J Diabetes Complications. 2017 Jan;31(1):228-233. doi: 10.1016/j.jdiacomp.2016.08.019. Epub 2016 Aug 28.
Kaido T, Tamai Y, Hamaguchi Y, Okumura S, Kobayashi A, Shirai H, Yagi S, Kamo N, Hammad A, Inagaki N, Uemoto S. Effects of pretransplant sarcopenia and sequential changes in sarcopenic parameters after living donor liver transplantation. Nutrition. 2017 Jan;33:195-198. doi: 10.1016/j.nut.2016.07.002. Epub 2016 Jul 27.
Kaido T, Tamai Y, Hamaguchi Y, Okumura S, Kobayashi A, Shirai H, Yagi S, Kamo N, Hammad A, Inagaki N, Uemoto S. Effects of pretransplant sarcopenia and sequential changes in sarcopenic parameters after living donor liver transplantation. Nutrition. 2017 Jan;33:195-198. doi: 10.1016/j.nut.2016.07.002. Epub 2016 Jul 27.
Ceriello A, Inagaki N. Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations. J Diabetes Investig. 2017 Jan;8(1):19-28. doi: 10.1111/jdi.12528. Epub 2016 Jul 21. Review.
